期刊文献+

基因工程双价抗体在肿瘤中的研究进展 被引量:4

Development of genetically engineered bivalent antibodies in tumor
在线阅读 下载PDF
导出
摘要 基因工程抗体技术的发展加速了单链抗体的应用,但其稳定性差,亲和力低,功能单一,体内清除过快等特点影响了它的广泛应用。双价抗体作为一种新型小分子抗体,具有双价的结合位点,能够使抗原分子上的两个表位交联或使两个分子连接,可以模拟完整的单克隆抗体的抗原抗体反应,其构建方法有亮氨酸拉链法、利用部分抗体恒定区法、连接肽法、利用双聚化结构法、knobs into holes技术等,在乳腺癌、直肠癌、淋巴瘤等的诊治方面均有很好的应用价值。 The development of genetically engineered antibodies technique accelerates the application of single chain antibody, but the characteristics including the poor stability, low affinity, single function, fast clearance affect their extensive application. Bivalent antibodies have two binding sites that can crosslink one antigen particle to another, or can allow antibodies to bind to muhimeric antigen with great avidity, so called a new antibody. They cause a visible reaction with specific antigen just as mono- clonal antibody. They can be constructed by means of leuzine zipper, constant region of antibodies, limker,etc and have a great potential in therapeutic and diagnostic aspects of breast cancer, colorectal cancer, lymphoma, and so on.
出处 《国际病理科学与临床杂志》 CAS 2008年第6期508-511,共4页 Journal of International Pathology and Clinical Medicine
关键词 双价抗体 基因工程 肿瘤 bivalent antibody genetically engineer neoplasms
  • 相关文献

参考文献20

  • 1Perez L, Ayala M, Pimentel G,et al. A multivalent recombinant antibody fragment specific for carcinoembryonic antigen [ J ]. Biotechnol Appl Biochem, 2006, 43 ( Ptl ) :39-48.
  • 2Kubetzko S, Balic E, Waibel R, et al. PEGylation and multimerization of the anti-p185HER-2 single chain Fv fragment 4D5: effects on tumor targeting [ J ]. J Bid Chem, 2006,281 (46) : 35186-35201.
  • 3de Kruif J, Logtenberg T. Leucine zipper dimerized bivalent and bispeciilcscFv antibodies from a semi-synthetic antibody phage display library[J].J Biol Chem, 1996,271 ( 13 ) :7630-7634.
  • 4Bera TK, Williams-Gould J, Beers R, et al. Bivalent disulfidestabilized fragment variable immunotoxin directed against mesotheliomas and ovarian cancer[J]. Mol Cancer Tiler, 2001, 1 (2) : 79-84.
  • 5郭建巍,蔡美英.新型小分子抗体scFv多聚体与肿瘤靶向[J].生物医学工程学杂志,2003,20(2):361-365. 被引量:5
  • 6高瀛岱,熊冬生,许元富,彭晖,邵晓枫,杨纯正,朱祯平.抗CD3/抗Pgp微型双功能抗体的构建和表达[J].生物工程学报,2003,19(4):444-449. 被引量:18
  • 7严丹丹,杨福辉,方瑾.抗人大肠癌双价单链抗体基因的构建及表达[J].世界华人消化杂志,2006,14(24):2395-2400. 被引量:8
  • 8王栋,王禾,武国军,吴卫真,杨顺良,林文洪,谭建明.抗人精浆蛋白/抗CD3双特异性单链抗体的活性研究[J].细胞与分子免疫学杂志,2006,22(4):500-503. 被引量:1
  • 9Hu S, Shively L, Raubitschck A,et al. Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (singlechain Fv-CH3 ) which exhibits rapid, high-level targeting of xenografts[J]. Cancer Res,1996,56(13) :3055-3061.
  • 10Xie Z, Guo N, Yu M, et al. A new format of bispecific antibody : highly efficient heterodimerization, expression and tumor cell lysis[J].J Immunol Methods, 2005, 296(1-2) :95-101.

二级参考文献34

  • 1RolandEKONTERMANN.Recombinant bispecific antibodies for cancer therapy[J].Acta Pharmacologica Sinica,2005,26(1):1-9. 被引量:10
  • 2白玉杰,杨安钢,苏成芝,王国华,王方,茹小荣.抗人CD_3单链抗体基因的构建及序列分析[J].细胞与分子免疫学杂志,1996,12(3):6-11. 被引量:12
  • 3SHEN D C YANG X F YANG C Yet al.Generation and characirization of monoclonal antibody againstHIT3a[J].Acta Academiae Medicinac Sinicac (中国医学科学院学报),199,15:157-162.
  • 4XIONG D S YANG C Z SHAO X Fet al.Generation and characterization of monoclonal antibodiesagainst P-glycoprolein(Pgp)[J]. Chin J HemoZo/( 中国血液学杂志),1999,20(6):326-327.
  • 5XUYF XIONGDS YANG C Z.The mutation of anti-CD3 antibody(H1T3a)gene and its ex-pression[J].Chin Jhematol(中国血液学杂志),2001,22(5):252-255.
  • 6[1]Farah RA, Clinchy B, Herrera L, et al. The development of monoclonal antibodies for the therapy of cancer. Crit Rev Eukaryot Gene Expr, 1998;8(3-4)∶321
  • 7[2]Ghetie MA,Podar EM,Ilgen Gordon BE,et al.Homodimerization of tumour reactive monoclonal antibodies markedly increases their ability to induce growth arrest of apoptosis of tumour cells. Proc Natl Acad Sci USA,1997;94∶7509
  • 8[3]Hudson PJ, Kortt AA. High avidity scFv multimers; diabodies and triabodies.J Immunol Methods, 1999;231(1-2)∶177
  • 9[4]Atwell JL, Breheney KA, Lawrence L, et al. scFv multimers of the anti-neuraminidase antibody NC10: length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies. Protein Eng, 1999;12(7)∶597
  • 10[5]Dolezal O,Pearce LA,Lawrence LJ,et al.scFv multimers of the anti-neuraminidase antibody NC10:shortening of the linker in single-chain formation of dimers,trimers,tetramers and higher molecular mass multimers.Protein Eng,2000;13∶565

共引文献28

同被引文献38

引证文献4

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部